The increasing volume and diversity of biomedical data generated daily from internal and external sources underscores the necessity for High-Quality data products and AI-assisted data consumption. This presentation will demonstrate a curation application that integrates large language models (LLMs) with a human-in-the-loop process to streamline the development of High-Quality data products. We will also explore how these data products facilitate the implementation of AI-driven text query systems, significantly enhancing data accessibility for researchers. This integration allows for effective navigation of complex, multimodal datasets, ultimately improving the efficiency of data consumption and supporting informed decision-making in biomedical research and development.
The increasing volume and diversity of biomedical data generated daily from internal and external sources underscores the necessity for High-Quality data products and AI-assisted data consumption. This presentation will demonstrate a curation application that integrates large language models (LLMs) with a human-in-the-loop process to streamline the development of High-Quality data products. We will also explore how these data products facilitate the implementation of AI-driven text query systems, significantly enhancing data accessibility for researchers. This integration allows for effective navigation of complex, multimodal datasets, ultimately improving the efficiency of data consumption and supporting informed decision-making in biomedical research and development.
Scaling clinico-genomic data integration: Large pharmaceutical organizations working with external data providers used Polly to build interoperable clinico-genomic data products 6x faster.
Although purchased datasets are often labeled as "clean," they still lack interoperability—Polly's pipelines bridge this gap with robust integration and harmonization.
Information Retrieval: Drug safety monitoring teams used Polly's Knowledge Graph powered co-scientist to conversationally retrieve the right cohorts & assess drug response—cutting discovery time by 70%.